Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CCR8 | P51685 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605252 | 0.83 | MEN1 (0.39) | ALOX15HTTGLO1MAPK1CA1 | |
| SCHEMBL1065843 | 0.83 | TDP1 (0.43) | ALOX15HTTTDP1MEN1KMT2A | |
| SCHEMBL5842794 | 0.81 | MAPT (0.42) | ALOX15HTTMAPK1CA1CA2 | |
| SCHEMBL5778919 | 0.78 | GLO1 (0.37) | ALOX15HTTGLO1MAPK1CA1 | |
| SCHEMBL5843572 | 0.77 | COMT (0.46) | ALOX15HTTGLO1MAPK1CA1 | |
| SCHEMBL27605709 | 0.76 | CCR1 (0.35) | TDP1MEN1KMT2APDE4APDE4B | |
| SCHEMBL4025246 | 0.73 | CYP2C9 (0.48) | ALOX15HTTGLO1MAPK1CA1 | |
| SCHEMBL6987990 | 0.73 | CCR1 (0.35) | ALOX15HTTTDP1PDE4APDE4B | |
| SCHEMBL4028251 | 0.72 | CYP2C9 (0.58) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6986883 | 0.71 | GLO1 (0.42) | ALOX15HTTGLO1MAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100508978-C | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK & CO INC MERCK FROSST CA (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-1363635-B1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| CN-1551769-A | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | — | 2004-12-01 | — | — | CN | disclosed |
| US-6740666-B2 | FOR THERAPY OF ASTHMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, EOSINOPHILIC GRANULOMA, PSORIASIS; SEPTIC SHOCK, ULCERATIVE COLITIS, CROHN'S DISEASE, REPERFUSION INJURY OF THE MYOCARDIUM AND BRAIN, INFLAMMATION | MERCK & CO., INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1363635-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | Merck & Co., Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-10-03 | — | — | US | disclosed |
| EP-1244628-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002069970-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO., INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | disclosed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | disclosed |
| WO-2001046151-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | ALOX15 4061/4885HTT 4205/4885GLO1 2958/4885 |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | ALOX15 2799/4885HTT 3299/4885GLO1 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.